SkyView Investment Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

SkyView Investment Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-151	Closed	-$23K	–	448
2021 Q2	$23K	Hold	151	–	–	0.01%	232
2021 Q1	$23K	Buy	151 +112	+287%	+$17.3K	0.01%	240
2020 Q4	$6K	Buy	+39	New	+$5.01K	﹤0.01%	235

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

SkyView Investment Advisors's ALXN Position: Q3 2021 in Review

SkyView Investment Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 151 shares — an estimated $23K sold.

SkyView Investment Advisors first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $23K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

SkyView Investment Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
SkyView Investment Advisors sold 151 Alexion Pharmaceuticals shares in Q3 2021, an estimated $23K.
SkyView Investment Advisors first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
SkyView Investment Advisors's Alexion Pharmaceuticals position peaked at $23K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on SkyView Investment Advisors's 13F filing for Q3 2021, filed 16 Nov 2021.